tiprankstipranks
Advertisement
Advertisement

ACRV Stock Latest News

Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
RatingsAcrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
4d ago
ACRV
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
PremiumRatings
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
6d ago
ACRV
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
PremiumRatings
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
6d ago
ACRV
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
PremiumThe Fly
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
7d ago
ACRV
Acrivon Highlights Positive ACR-368 Data and 2025 Results
PremiumCompany Announcements
Acrivon Highlights Positive ACR-368 Data and 2025 Results
2M ago
8K
ACRV
Acrivon plans to initiate fourth cohort in ACR-368 Phase 2b study
PremiumThe FlyAcrivon plans to initiate fourth cohort in ACR-368 Phase 2b study
2M ago
ACRV
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
Premium
The Fly
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
2M ago
ACRV
Acrivon Therapeutics sees cash runway into 2Q27
Premium
The Fly
Acrivon Therapeutics sees cash runway into 2Q27
2M ago
ACRV
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
PremiumRatings
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
3M ago
ACRV
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
PremiumCompany Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
3M ago
8K
ACRV
Acrivon Therapeutics announces completion, certification of CLIA certified lab
PremiumThe Fly
Acrivon Therapeutics announces completion, certification of CLIA certified lab
3M ago
ACRV
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
4M ago
ACRV
META
Acrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
PremiumThe FlyAcrivon Therapeutics price target raised to $8 from $6 at Piper Sandler
4M ago
ACRV
Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
Premium
Ratings
Balancing Early Promise and Significant Uncertainty: Maintaining a Hold on Acrivon Therapeutics Amid Limited Data and Long-Dated Clinical Risk
4M ago
ACRV
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
Premium
Ratings
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating
4M ago
ACRV
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
4M ago
F
AEP
Acrivon Showcases Promising Phase 2b Oncology Data Update
PremiumCompany Announcements
Acrivon Showcases Promising Phase 2b Oncology Data Update
4M ago
8K
ACRV
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
PremiumMarket News
Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results
4M ago
ACRV
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
PremiumCompany Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
4M ago
8K
ACRV
Acrivon Therapeutics announces progress across pipeline
PremiumThe FlyAcrivon Therapeutics announces progress across pipeline
4M ago
ACRV
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies
Premium
The Fly
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies
4M ago
ACRV
Acrivon to provide ACR-368, ACR-2316 clinical data in January
Premium
The Fly
Acrivon to provide ACR-368, ACR-2316 clinical data in January
5M ago
ACRV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >